22 results on '"Harty, Gail"'
Search Results
2. 037 - Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure
3. Gene Expression Profiling in Experimental Early Stage Heart Failure Reveals Activation of Molecular Pathways of Fibrosis and Inflammation in the Kidney and Heart
4. M-Atrial Natriuretic Peptide: A Novel Designer Natriuretic Peptide with Sustained Blood Pressure Lowering and Cyclic GMP Activating Actions in a Chronic Canine Model of Angiotensin II-Induced Hypertension
5. Pro-Atrial Natriuretic Peptide In Vitro and In Vivo Normal Canines: A Selective Renal Enhancing Therapeutic
6. A Novel Chimeric Peptide, ANG1-7/BNP, with Dual In Vitro and In Vivo Actions through the Natriuretic Peptide Receptor and Mas Receptor Systems
7. Progressive Bi-Ventricular Dysfunction in a Large Animal Model of Heart Failure With Rapid Ventricular Pacing: Echocardiographic Parameters and Invasive Characterization
8. Impaired Cardiorenal Adaptation to Acute Heart Failure and Volume Expansion in a Large Animal Model of Mild Renal Insufficiency: New Insights Into the Kidney-Heart Connection
9. Renal Mechanisms of Action of a Novel Designer Natriuretic Peptide, CU-NP
10. Dipeptidyl Peptidase IV Inhibition with Sitagliptin Augments cGMP-Activating and Hypotensive Properties of B-Type Natriuretic Peptide
11. Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure
12. Neurohormonal Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide, in the Normal Dog
13. Co-Targeting of the V2 Receptor with Tolvaptan and the Natriuretic Peptide A-Receptor with B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal Function: A Novel Physiologic Approach to Sodium and Water Retention in Experimental Heart Failure
14. Renal actions of the cancion® Cardiac Recovery System in severe experimental heart failure
15. Sildenafil, a phosphodiesterase V inhibitor potentiates the renal actions of subcutaneously administered BNP without adverse hemodynamic effects in experimental overt heart failure
16. Defining the acute cardiorenal response to high dose nesiritide in experimental severe congestive heart failure
17. BNP enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in canine experimental heart failure
18. Cardiorenal actions of the new heme-independent direct soluble guanylate cyclase activator BAY 58-2667 in experimental congestive heart failure
19. Mineralocorticoid excess does not result in Sodium retention but in cardiac fibrosis in experimental asymptomatic left ventricular dysfunction
20. Therapeutic actions of a novel natriuretic peptide in experimental overt congestive heart failure
21. Acute NEP/ACE inhibition by omapatrilat is superior to ace inhibition alone in mediating favorable cardiorenal and humoral actions in mild heart failure
22. Survey of distribution of substance P, vasoactive intestinal polypeptide, cholecystokinin, neurotensin, Met-enkephalin, bombesin and PHI in the spinal cord of cat, dog, sloth and monkey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.